NCT05906524View on ClinicalTrials.gov

KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 15, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

December 31, 2025

Conditions

Advanced HCCOther Solid Tumors

Interventions

DRUG

KD6001

KD6001 will be administered intravenously.

DRUG

Tislelizumab

Tislelizumab will be administered intravenously.

DRUG

Bevacizumab

Bevacizumab will be administered intravenously.

Trial Locations (1)

Unknown

Zhongshan Hospital, Shanghai

All Listed Sponsors

lead

Shanghai Kanda Biotechnology Co., Ltd.

INDUSTRY

NCT05906524 - KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors | Biotech Hunter | Biotech Hunter